Trial Profile
The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Losartan/hydrochlorothiazide (Primary) ; Losartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms MAPPY
- 29 Sep 2016 Results of subanalysis (safety and efficacy in very elderly patients) presented at the 26th Scientific Meeting of the International Society of Hypertension
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
- 01 Jul 2012 Primary endpoints 'Morning-blood-pressure' and 'Target-achievement-rate' have been met according to results published in Hypertension Research.